Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Down 35.2% in January

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) was the target of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 23,700 shares, a decline of 35.2% from the December 31st total of 36,600 shares. Based on an average trading volume of 43,400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.7% of the company’s shares are short sold.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC acquired a new position in Lakeshore Biopharma during the 3rd quarter worth approximately $169,000. Hhlr Advisors LTD. purchased a new stake in shares of Lakeshore Biopharma during the 3rd quarter worth approximately $513,000. Finally, FMR LLC purchased a new stake in shares of Lakeshore Biopharma during the 3rd quarter worth approximately $803,000. Institutional investors and hedge funds own 52.64% of the company’s stock.

Lakeshore Biopharma Trading Down 1.1 %

Shares of LSB stock opened at $2.72 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.90 and a current ratio of 1.17. The company has a 50 day moving average price of $2.87 and a 200 day moving average price of $3.91. Lakeshore Biopharma has a fifty-two week low of $1.88 and a fifty-two week high of $11.20.

About Lakeshore Biopharma

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.